Related Experiment Videos
Long-term bone-marrow damage in children treated for ALL: evidence from in vitro colony assays (GM-CFC and CFUF)
Insights
Children treated for acute lymphoblastic leukemia (ALL) showed normal granulocyte-macrophage progenitor cells (GM-CFC) after standard chemotherapy. However, those with relapses and additional therapy had reduced GM-CFC, indicating potential long-term bone marrow damage.
Area of Science:
- Hematology
- Pediatric Oncology
- Stem Cell Biology
Background:
- Acute lymphoblastic leukemia (ALL) is a common childhood cancer.
- Chemotherapy is a primary treatment for ALL, but can have long-term side effects.
- Hematopoietic stem and progenitor cells are crucial for blood cell formation.
Purpose of the Study:
- To assess long-term bone marrow damage in children treated for ALL.
- To evaluate the incidence of granulocyte-macrophage progenitor cells (GM-CFC) after ALL treatment.
- To investigate the impact of standard versus intensive chemotherapy regimens on hematopoietic recovery.
Main Methods:
- Serial bone marrow aspirates were collected from 43 children in remission from ALL.
- Granulocyte-macrophage progenitor cell (GM-CFC) incidence was measured.
- Results were compared between patients receiving standard chemotherapy and those with additional therapy for relapses.
- GM-CFC incidence was normalized to non-hematopoietic progenitor cells (CFU-F).
Main Results:
- Children receiving standard chemotherapy for ALL showed no evidence of long-term bone marrow damage regarding GM-CFC levels.
- Patients who received additional therapy for relapses exhibited a significantly reduced mean incidence of GM-CFC.
- This reduction in GM-CFC was also observed when normalized to CFU-F, suggesting specific impact on hematopoietic progenitors.
Conclusions:
- Standard chemotherapy for childhood ALL appears to have minimal long-term impact on GM-CFC.
- Intensified treatment regimens or relapses in ALL may lead to persistent reduction in GM-CFC.
- Further research is needed to understand the clinical implications of reduced GM-CFC in ALL survivors.
Abstract:
We have studied granulocyte-macrophage progenitor cells (GM-CFC) in serial bone marrow aspirates from 43 children who had been treated for acute lymphoblastic leukaemia (ALL). All patients were in full remission, not receiving anti-leukaemic therapy and 42 out of the 43 had normal peripheral blood counts. Thirty-seven patients have received standard amounts of chemotherapy and 6 have received additional therapy for relapses occurring in the first treatment-free interval. In the former group estimation of GM-CFC incidence did not provide evidence of long-term residual bone-marrow damage. In the latter, however, the mean incidence of GM-CFC was significantly reduced. This reduction was also apparent when the incidence of GM-CFC was related to the incidence of non-haemopoietic progenitor cells within the marrow (CFU-F).